Scarica l'app Stockscreener
1.18
3.28%
-0.04
Dopo l'orario di chiusura:
1.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Precedente Chiudi:
$1.22
Aprire:
$1.15
Volume 24 ore:
962.71K
Relative Volume:
0.71
Capitalizzazione di mercato:
$31.95M
Reddito:
$642.00K
Utile/perdita netta:
$-69.90M
Rapporto P/E:
-0.165
EPS:
-7.152
Flusso di cassa netto:
$-57.62M
1 W Prestazione:
-13.87%
1M Prestazione:
-27.61%
6M Prestazione:
-55.30%
1 anno Prestazione:
-40.70%
Intervallo 1D:
$1.08
$1.22
Intervallo di 1 settimana:
$1.08
$1.42
Portata 52W:
$1.08
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Nome
Bioxcel Therapeutics Inc
Settore
Telefono
203-643-8060
Indirizzo
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.18 | 31.95M | 642.00K | -69.90M | -57.62M | -7.152 |
TAK
Takeda Pharmaceutical Co Adr
|
18.74 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.94 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.93 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.08 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
564.81 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Iniziato | Rodman & Renshaw | Buy |
| 2024-02-21 | Downgrade | UBS | Buy → Neutral |
| 2023-08-15 | Downgrade | Mizuho | Buy → Neutral |
| 2023-07-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-03-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-01 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-06 | Reiterato | BofA Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-30 | Iniziato | Goldman | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-04 | Iniziato | Guggenheim | Buy |
| 2020-04-01 | Iniziato | BofA/Merrill | Buy |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
Mostra tutto
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
BioXcel Therapeutics Inc. (BX20.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
BTAI Should I Buy - Intellectia AI
H.C. Wainwright cuts BioXcel Therapeutics price target on dilution By Investing.com - Investing.com Australia
H.C. Wainwright cuts BioXcel Therapeutics price target on dilution - Investing.com
BTAI: HC Wainwright & Co. Lowers Price Target, Maintains Buy Rat - GuruFocus
H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
FDA accepts BioXcel filing for at-home agitation treatment By Investing.com - Investing.com South Africa
BTAI Technical Analysis & Stock Price Forecast - Intellectia AI
BioXcel Therapeutics, Inc. (BTAI) Stock Price, News, Quote & History - ca.finance.yahoo.com
BioXcel Therapeutics, Inc. (BTAI) stock price, news, quote and history - Yahoo Finance Singapore
FDA accepts BioXcel filing for at-home use of agitation drug - Investing.com Australia
BTAI: FDA Reviews BioXcel's Home Use Application for Igalmi - GuruFocus
FDA Accepts BioXcel sNDA for At-Home IGALMI Use - TipRanks
BioXcel Therapeutics Announces Food and Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting - marketscreener.com
FDA accepts BioXcel Therapeutics application for IGALMI in at-home agitation treatment - Investing.com UK
FDA accepts BioXcel filing for at-home agitation treatment - Investing.com
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting - The Manila Times
BioXcel seeks first at-home FDA-approved agitation treatment - Stock Titan
BioXcel Therapeutics (BTAI) gets FDA review date for IGALMI at-home agitation use - Stock Titan
BTAI.O Forecast — Price Prediction for 2026. Should I Buy BTAI.O? - Intellectia AI
BTAI.O PE Ratio & Valuation, Is BTAI.O Overvalued - Intellectia AI
BTAI.O Technical Analysis & Stock Price Forecast - Intellectia AI
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting - Bitget
Certain Common Stock of BioXcel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Certain Warrants of BioXcel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - MarketScreener
BTAI SEC FilingsBioxcel Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Why are BioXcel Therapeutics shares down Friday? - MSN
Bank of America Securities Remains a Sell on Bioxcel Therapeutics (BTAI) - The Globe and Mail
Qatar Investment Authority (BTAI) reports 156,066 BioXcel shares owned - Stock Titan
Pharvaris (NASDAQ:PHVS) versus BioXcel Therapeutics (NASDAQ:BTAI) Critical Comparison - Defense World
Free cash flow per share of BioXcel Therapeutics, Inc. – FWB:BX20 - TradingView
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks - finance.yahoo.com
SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - accessnewswire.com
BioXcel Therapeutics, Inc. 2025 Annual Report Highlights: Business Overview, Risk Factors, and Forward-Looking Statements - Minichart
BioXcel Therapeutics Inc. R (BX20.F) Analyst Ratings, Estimates & Forecasts - Yahoo! Finance Canada
BioXcel Therapeutics (NASDAQ: BTAI) bets on BXCL501 at-home use - stocktitan.net
BioXcel Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
BioXcel Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioXcel Therapeutics reports Q4 & FY2025 results; FY revenue $642k, net loss $69.9M - TradingView
BTAI: IGALMI at-home sNDA submitted; revenue down, cost controls in place, large market targeted - TradingView
BioXcel (NASDAQ: BTAI) flags going concern as IGALMI label bid advances - Stock Titan
AI-driven biopharma firm BioXcel Therapeutics posts lower-than-expected Q4 loss on reduced SG&A costs - TradingView
Earnings Scheduled For March 27, 2026 - Benzinga
BRIEF-BioXcel Therapeutics Q4 Basic EPS USD -0.58 Vs. IBES Estimate USD -0.75 - TradingView
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting - ChartMill
BioXcel Therapeutics 2025 10-K: Revenue $0.642M, Net Loss $(69.897)M - TradingView
ETF Watch: Is BioXcel Therapeutics Inc benefiting from interest rate changes2026 Highlights & Target Return Focused Picks - baoquankhu1.vn
BioXcel Therapeutics $9.75M Class Action Settlement - Claim Depot
Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc. - GlobeNewswire Inc.
Why did BTAI stock surge 20% in pre-market today? - MSN
If You Invested $1,000 in Bioxcel Therapeutics Inc (BTAI) - Stock Titan
Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):